Dose of Inhaled Corticosteroids and Cardiovascular Disease in Asthma: An Unexpected Misstep?
作者信息
Rogliani Paola, Calzetta Luigino
机构信息
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; and.
Respiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
出版信息
Am J Respir Crit Care Med. 2025 Feb;211(2):292-293. doi: 10.1164/rccm.202409-1788LE.
Abstract
摘要
相似文献
1
Dose of Inhaled Corticosteroids and Cardiovascular Disease in Asthma: An Unexpected Misstep?吸入性糖皮质激素剂量与哮喘患者的心血管疾病：一次意外的失误？
Am J Respir Crit Care Med. 2025 Feb;211(2):292-293. doi: 10.1164/rccm.202409-1788LE.
2
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.在患有持续性哮喘的成人和儿童中，长效β2受体激动剂与高剂量吸入性类固醇联合使用与单纯使用高剂量吸入性类固醇的比较。
Cochrane Database Syst Rev. 2010 Apr 14(4):CD005533. doi: 10.1002/14651858.CD005533.pub2.
3
Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.吸入长效β2受体激动剂与吸入性糖皮质激素联合使用与高剂量吸入性糖皮质激素治疗儿童和成人持续性哮喘的比较
Cochrane Database Syst Rev. 2005 Oct 19(4):CD005533. doi: 10.1002/14651858.CD005533.
4
Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.对于未使用过类固醇的成人和儿童持续性哮喘，吸入长效β2受体激动剂联合吸入性类固醇作为一线治疗方案。
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD005307. doi: 10.1002/14651858.CD005307.pub2.
5
Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma.高剂量吸入性糖皮质激素对哮喘患者细胞介导免疫的影响。
Allergol Immunopathol (Madr). 2012 Mar-Apr;40(2):100-3. doi: 10.1016/j.aller.2011.11.001. Epub 2012 Jan 10.
6
Initial corticosteroid therapy for asthma.哮喘的初始皮质类固醇治疗。
Curr Opin Pulm Med. 2006 Jan;12(1):48-53. doi: 10.1097/01.mcp.0000199808.64882.12.
7
Efficacy of inhaled corticosteroids in asthma.吸入性糖皮质激素在哮喘治疗中的疗效。
J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):531-8. doi: 10.1016/s0091-6749(98)70268-4.
8
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children.福莫特罗与布地奈德联合作为维持和缓解治疗与吸入性糖皮质激素维持治疗对成人和儿童慢性哮喘的疗效比较
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007313. doi: 10.1002/14651858.CD007313.pub2.
9
Successful withdrawal of inhaled corticosteroids in childhood asthma.儿童哮喘中吸入性糖皮质激素的成功撤药
Respirology. 2005 Jun;10(3):385-8. doi: 10.1111/j.1440-1843.2005.00708.x.
10
Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.吸入性糖皮质激素与长效β受体激动剂联合作为持续性哮喘控制和快速缓解治疗与病情加重及症状控制的关联：一项系统评价和荟萃分析
JAMA. 2018 Apr 10;319(14):1485-1496. doi: 10.1001/jama.2018.2769.
本文引用的文献
1
Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events.吸入性糖皮质激素剂量与不良事件发生频率的关联
Am J Respir Crit Care Med. 2024 Aug 1;211(1):54-63. doi: 10.1164/rccm.202402-0368OC.
2
Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies.含中剂量吸入性糖皮质激素的固定剂量复方制剂可降低慢性阻塞性肺疾病患者的全因死亡率：对双联和三联疗法的深入分析
Expert Rev Respir Med. 2022 Mar;16(3):357-365. doi: 10.1080/17476348.2021.1951237. Epub 2021 Jul 31.
3
Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review.哮喘患者吸入皮质类固醇的全身不良反应：系统评价。
BMJ Open Respir Res. 2020 Dec;7(1). doi: 10.1136/bmjresp-2020-000756.
4
Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: A population-based observational study.2001-2017 年英国患者降低哮喘药物治疗的健康和成本影响：基于人群的观察性研究。
PLoS Med. 2020 Jul 21;17(7):e1003145. doi: 10.1371/journal.pmed.1003145. eCollection 2020 Jul.
5
Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma.哮喘患者使用丙酸倍氯米松细颗粒或大颗粒制剂的真实生活比较。
Respir Med. 2013 Jul;107(7):987-1000. doi: 10.1016/j.rmed.2013.03.009. Epub 2013 May 3.
Zotero 插件